Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Meningiomas: skull base versus non-skull base

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Meling, Torstein R ; Da Broi, Michele ; Scheie, David ; Helseth, Eirik. / Meningiomas : skull base versus non-skull base. I: Journal of Neurosurgery. 2019 ; Bind 42, Nr. 1. s. 163-173.

Bibtex

@article{4130771c454d4b9e8609a6236a29030d,
title = "Meningiomas: skull base versus non-skull base",
abstract = "To identify differences between skull base meningiomas (SBM) and non-skull base meningiomas (NSBM). All adult patients (18.0-69.9 years) operated for intracranial meningiomas between 1990 and 2010 at our institution were investigated. Al-Mefty's definition was used to dichotomize tumors into SBM and NSBM. Overall, 1148 consecutive patients were identified. Median age at surgery was 54.2 years [18.1-69.9]. Median follow-up was 7.4 years [0.0-20.9]. There were 562 patients (49%) with SBM and 586 (51%) with NSBM. The two groups were similar with respect to patient age, follow-up time, and number of patients. Overall female-to-male ratio was 2.6:1, but 3.2:1 in SBM and 2.2:1 in NSBM (p < 0.005). With respect to presenting symptoms, SBMs had more often neurological deficits (risk ratio (RR) 1.4; p < 0.0001) and less often seizures (RR 0.4; p < 0.0001). Gross total resections were less frequent in SBM than NSBM (62 vs 84%) (RR 1.3; p < 0.0001). SBMs had a lower risk of WHO grades II and III histology (4.5 vs 9.5%) (RR 0.5; p < 0.001). Worsening of neurological function was more frequent in SBM (21 vs 121%) (RR 1.8; p < 0.001). Retreatment-free survival at 5, 10, and 15 years, respectively, was 80, 70, and 62% for SBM versus 90, 82, and 74% for NSBM (p < 0.0001). Overall survival at 5, 10, and 15 years, respectively, was 93, 85, and 78% for SBM and 96, 91, and 79% for NSBM (p = 0.14). Patients with SBMs had more new-onset neurological deficits and significantly shorter retreatment-free survivals, but this did not adversely affect the overall survival.",
keywords = "Craniotomy, Intracranial tumor, Meningioma, Overall survival, Retreatment-free survival, Age Factors, Follow-Up Studies, Humans, Middle Aged, Male, Nervous System Diseases/etiology, Reoperation/statistics & numerical data, Young Adult, Meningeal Neoplasms/pathology, Meningioma/pathology, Adult, Female, Treatment Outcome, Seizures/etiology, Progression-Free Survival, Adolescent, Sex Factors, Survival Analysis, Aged, Skull Base Neoplasms/pathology",
author = "Meling, {Torstein R} and {Da Broi}, Michele and David Scheie and Eirik Helseth",
year = "2019",
month = mar,
doi = "10.1007/s10143-018-0976-7",
language = "English",
volume = "42",
pages = "163--173",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "1",

}

RIS

TY - JOUR

T1 - Meningiomas

T2 - skull base versus non-skull base

AU - Meling, Torstein R

AU - Da Broi, Michele

AU - Scheie, David

AU - Helseth, Eirik

PY - 2019/3

Y1 - 2019/3

N2 - To identify differences between skull base meningiomas (SBM) and non-skull base meningiomas (NSBM). All adult patients (18.0-69.9 years) operated for intracranial meningiomas between 1990 and 2010 at our institution were investigated. Al-Mefty's definition was used to dichotomize tumors into SBM and NSBM. Overall, 1148 consecutive patients were identified. Median age at surgery was 54.2 years [18.1-69.9]. Median follow-up was 7.4 years [0.0-20.9]. There were 562 patients (49%) with SBM and 586 (51%) with NSBM. The two groups were similar with respect to patient age, follow-up time, and number of patients. Overall female-to-male ratio was 2.6:1, but 3.2:1 in SBM and 2.2:1 in NSBM (p < 0.005). With respect to presenting symptoms, SBMs had more often neurological deficits (risk ratio (RR) 1.4; p < 0.0001) and less often seizures (RR 0.4; p < 0.0001). Gross total resections were less frequent in SBM than NSBM (62 vs 84%) (RR 1.3; p < 0.0001). SBMs had a lower risk of WHO grades II and III histology (4.5 vs 9.5%) (RR 0.5; p < 0.001). Worsening of neurological function was more frequent in SBM (21 vs 121%) (RR 1.8; p < 0.001). Retreatment-free survival at 5, 10, and 15 years, respectively, was 80, 70, and 62% for SBM versus 90, 82, and 74% for NSBM (p < 0.0001). Overall survival at 5, 10, and 15 years, respectively, was 93, 85, and 78% for SBM and 96, 91, and 79% for NSBM (p = 0.14). Patients with SBMs had more new-onset neurological deficits and significantly shorter retreatment-free survivals, but this did not adversely affect the overall survival.

AB - To identify differences between skull base meningiomas (SBM) and non-skull base meningiomas (NSBM). All adult patients (18.0-69.9 years) operated for intracranial meningiomas between 1990 and 2010 at our institution were investigated. Al-Mefty's definition was used to dichotomize tumors into SBM and NSBM. Overall, 1148 consecutive patients were identified. Median age at surgery was 54.2 years [18.1-69.9]. Median follow-up was 7.4 years [0.0-20.9]. There were 562 patients (49%) with SBM and 586 (51%) with NSBM. The two groups were similar with respect to patient age, follow-up time, and number of patients. Overall female-to-male ratio was 2.6:1, but 3.2:1 in SBM and 2.2:1 in NSBM (p < 0.005). With respect to presenting symptoms, SBMs had more often neurological deficits (risk ratio (RR) 1.4; p < 0.0001) and less often seizures (RR 0.4; p < 0.0001). Gross total resections were less frequent in SBM than NSBM (62 vs 84%) (RR 1.3; p < 0.0001). SBMs had a lower risk of WHO grades II and III histology (4.5 vs 9.5%) (RR 0.5; p < 0.001). Worsening of neurological function was more frequent in SBM (21 vs 121%) (RR 1.8; p < 0.001). Retreatment-free survival at 5, 10, and 15 years, respectively, was 80, 70, and 62% for SBM versus 90, 82, and 74% for NSBM (p < 0.0001). Overall survival at 5, 10, and 15 years, respectively, was 93, 85, and 78% for SBM and 96, 91, and 79% for NSBM (p = 0.14). Patients with SBMs had more new-onset neurological deficits and significantly shorter retreatment-free survivals, but this did not adversely affect the overall survival.

KW - Craniotomy

KW - Intracranial tumor

KW - Meningioma

KW - Overall survival

KW - Retreatment-free survival

KW - Age Factors

KW - Follow-Up Studies

KW - Humans

KW - Middle Aged

KW - Male

KW - Nervous System Diseases/etiology

KW - Reoperation/statistics & numerical data

KW - Young Adult

KW - Meningeal Neoplasms/pathology

KW - Meningioma/pathology

KW - Adult

KW - Female

KW - Treatment Outcome

KW - Seizures/etiology

KW - Progression-Free Survival

KW - Adolescent

KW - Sex Factors

KW - Survival Analysis

KW - Aged

KW - Skull Base Neoplasms/pathology

U2 - 10.1007/s10143-018-0976-7

DO - 10.1007/s10143-018-0976-7

M3 - Journal article

C2 - 29627874

VL - 42

SP - 163

EP - 173

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 1

ER -

ID: 56537714